Research finds Sotagliflozin may be first drug to improve glucose control without weight gain or increase in severe hypoglycemia.
A University of Colorado Anschutz Medical Campus study finds Sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Principal results were published today in the New England Journal of Medicine. This drug is in phase 3 clinical trials. Among 1,402 trial participants given the drug, Sotagliflozin showed clinically meaningful and statistically significant effects on glucose control. A1C, was also significantly improved without severe hypoglycemia. Patients also had weight loss.
Sotagliflozin has the potential to become the first new treatment innovation in nearly a century since insulin.
Most patients do not achieve optimal glycemic control with insulin alone. A1C concentrations, hypertension and reduction in body weight are critical issues which significantly impact people living with type 1 diabetes.
"If approved by the FDA, Sotagliflozin may be the first oral drug that helps patients with type 1 diabetes in improving their glucose control without any weight gain increase and severe hypoglycemia," Garg said. "If long-term use continues to show similar metabolic improvements in patients with type 1 diabetes, it is likely that the long-term complications of diabetes would be significantly reduced."
Sotagliflozin would be used in conjunction with insulin. Trial participants taking the drug as an oral pill alongside traditional insulin treatments experienced significant improvements in glucose control, a drop in systolic and diastolic blood pressure and weight loss.
New England Journal of Medicine
A University of Colorado Anschutz Medical Campus study finds Sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Principal results were published today in the New England Journal of Medicine. This drug is in phase 3 clinical trials. Among 1,402 trial participants given the drug, Sotagliflozin showed clinically meaningful and statistically significant effects on glucose control. A1C, was also significantly improved without severe hypoglycemia. Patients also had weight loss.
Sotagliflozin has the potential to become the first new treatment innovation in nearly a century since insulin.
Most patients do not achieve optimal glycemic control with insulin alone. A1C concentrations, hypertension and reduction in body weight are critical issues which significantly impact people living with type 1 diabetes.
"If approved by the FDA, Sotagliflozin may be the first oral drug that helps patients with type 1 diabetes in improving their glucose control without any weight gain increase and severe hypoglycemia," Garg said. "If long-term use continues to show similar metabolic improvements in patients with type 1 diabetes, it is likely that the long-term complications of diabetes would be significantly reduced."
Sotagliflozin would be used in conjunction with insulin. Trial participants taking the drug as an oral pill alongside traditional insulin treatments experienced significant improvements in glucose control, a drop in systolic and diastolic blood pressure and weight loss.
New England Journal of Medicine